

PATIENT: MR. GAURAV KATHURIA	AGE &SEX :34Y/M	
REF; BY ; MEDI WHEEL	DATE: 22.10.2023	

OPHTHALMIC VISION TESTING

EYE: RT. EYE LT.EYE

DISTANCE: 6/6 6/6

NEAR: N5/Vellnes N5

COLOUR VISION: Normal

Dr. RAKESYI SHARMA M.S. OP M. P. OP TH FIGUR





PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 REF. DOCTOR : SELF

ACCESSION NO: 0251WJ001889
PATIENT ID: AURAM211089251
CLIENT PATIENT ID: 0123102140047

ABHA NO :

AGE/SEX : 34 Years Male
DRAWN :21/10/2023 12:59:00
RECEIVED :21/10/2023 13:10:02
REPORTED :22/10/2023 14:56:18

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY - CBC							
MEDI WHEEL FULL BODY HEALTH CHECK UP BE	MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE						
BLOOD COUNTS, EDTA WHOLE BLOOD							
HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION	13.9	13.0 - 17.0	g/dL				
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.67	4.5 - 5.5	mil/μL				
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	6.70	4.0 - 10.0	thou/µL				
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	182	150 - 410	thou/µL				
RBC AND PLATELET INDICES							
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	42.0	40 - 50	%				
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED PARAMETER	90.0	83 - 101	rL.				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.8	27.0 - 32.0	pg				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALQUATED PARAMETER	33.2	31.5 - 34.5	g/dL				
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	12.8	11.6 - 14.0	96				
MENTZER INDEX	19.3						
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	10.5	6.8 - 10.9	rL.				
WBC DIFFERENTIAL COUNT	WBC DIFFERENTIAL COUNT						
NEUTROPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	51	40 - 80	96				
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	38	20 - 40	96				
MONOCYTES	04	2 - 10	%				

Dr. Akansha Jain Consultant Pathologist



Page 1 Of 17

View Details

View Report









PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047

ABHA NO

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED: 21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY EOSINOPHILS	07 High	1 - 5	96
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY BASOPHILS	00	0 - 2	96
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY ABSOLUTE NEUTROPHIL COUNT	3.42	2.0 - 7.0	thou/µL
METHOD : CALQULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT	2,55	1.0 - 3.0	thou/µL
METHOD: CALQULATED PARAMETER ABSOLUTE MONOCYTE COUNT	0.27	0.2 - 1.0	thou/µL
METHOD: CALCULATED PARAMETER ABSOLUTE FOSINOPHIL COUNT	0.47	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3	0.02 - 0.10	tilou/ pt

Shoot Counts, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentaer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) (< 13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thelassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020)

106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain Consultant Pathologist Page 2 Of 17













PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO : **0251WJ001889**PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047

ABHA NO

AGE/SEX : 34 Years Male
DRAWN :21/10/2023 12:59:00

RECEIVED : 21/10/2023 13:10:02 REPORTED : 22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.9 High

Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

< 116.0

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)

ande dededde(end)

122.6 High

mg/dL

96

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist Page 3 Of 17





View Details

View Report







PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID: : AURAM211089251 CLIENT PATIENT ID: 0123102140047

AGE/SEX : 34 Years Male ;21/10/2023 12:59:00 DRAWN RECEIVED: 21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

mm at 1 hr E.S.R. 0 - 14

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)*

d>rterpretation(s)</br>
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-
b>Used For</br>

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for wellcontrolled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

eAG (Estimated average glucose) converts percentage HbAIc to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 " HbAIc - 46.7

-

 anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilinubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinogathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

of New Section of the Section of the Section of the Section of the Section of that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.GRP is superior to ESR because it is more sensitive and reflects a more rapid change.

b>TEST INTERPRETATION

Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocanditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

<br

 salicylates)

REFERENCE:
1. Nethan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition."

Dr. Akansha Jain Consultant Pathologist





Page 4 Of 17







PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251 CLIENT PATIENT ID: 0123102140047

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED: 21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 5 Of 17













PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: **0251WJ001889**PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047

ABHA NO

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02

REPORTED :22/10/2023 14:56:18

ı	Test Report Status	Final	Results	Riolog	nical	Reference	Interval	Units
ı	Commercial and Commercial Commerc		TO SALES TO LAND	DIVIO	arcan	Kererence	THICKIAN	THE RESIDENCE

r			
	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOW 40 MALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	88	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	110	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	277 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: CHOLESTEROL OXIDASE TRIGLYCERIDES	380 High	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : LIPASE/GPO-PAP NO CORRECTION HDL CHOLESTEROL	30 Low	< 40 Low	ma/dl
HDL CHOLESTEROL	30 LOW	>/=60 High	mg/dL
METHOD: DIRECT CLEARANCE METHOD	242 111-1		man fell
NON HDL CHOLESTEROL	247 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD: CALCULATED PARAMETER VERY LOW DENSITY LIPOPROTEIN	76.0 High	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	9.2 High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0	

Dr. Akansha Jain Consultant Pathologist





Page 6 Of 17

View Details











PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030**

8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047 ABHA NO

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED: 21/10/2023 13:10:02

REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

> Moderate Risk > 11.0 High Risk

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category					
Extreme risk group	A.CAD with > 1 feature of high risk group				
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =			
	50 mg/dl or polyvascular disease				
Very High Risk	 Established ASCVD 2. Diabetes with 2 r 	najor risk factors or evidence of end organ damage 3.			
	Familial Homozygous Hypercholesterolemia	1			
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ				
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary				
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque				
Moderate Risk	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors				
Major ASCVD (Athe	erosclerotic cardiovascular disease) Risk Fa	ctors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of p	Family history of premature ASCVD 4. High blood pressure				
5. Low HDL					

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80	
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>			
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR= 100	
Moderate Risk	<100	<130	>OR= 100	>OR= 130	
Low Risk	<100	<130	>OR= 130*	>OR= 160	

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

0.850 - 1mg/dL BILIRUBIN, TOTAL METHOD: DIAZO WITH SULPHANILIC ACID BILIRUBIN, DIRECT 0.200.00 - 0.25mg/dL

Dr. Akansha Jain **Consultant Pathologist**



Page 7 Of 17









PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 REF. DOCTOR: SELF

ACCESSION NO: 0251WJ001889
PATIENT ID: AURAM211089251
CLIENT PATIENT ID: 0123102140047

ABHA NO :

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

	<u> </u>		
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
METHOD: DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, INDIRECT	0.65	0.1 - 1.0	mg/dL
METHOD: CALCULATED PARAMETER TOTAL PROTEIN	7.8	6.4 - 8.2	g/dL
METHOD: BIURET REACTION, END POINT			
ALBUMIN	4.8 High	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN			
GLOBULIN	3.0	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER	1.6	10 31	RATIO
ALBUMIN/GLOBULIN RATIO NETHOD: CALCULATED PARAMETER	1.0	1.0 - 2.1	KAIIO
ASPARTATE AMINOTRANSFERASE	34	0 - 37	U/L
(AST/SGOT)			-
METHOD: TRIS BUFFER NO PSP IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	49 High	0 - 40	U/L
METHOD: TRIS BUFFER NO PSP IFCC / SFBC 37° C ALKALINE PHOSPHATASE	77	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C	//	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	59 High	11 - 50	U/L
METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	-	22 50	
LACTATE DEHYDROGENASE	349	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	10	5.0 - 18.0	mg/dL
METHOD: UREASE KINETIC			
CREATININE, SERUM			
CREATININE	1.00	0.8 - 1.3	mg/dL
METHOD: ALKALINE PICRATE NO DEPROTEINIZATION	m = 50° 50°	SCISC WILL	

BUN/CREAT RATIO

BUN/CREAT RATIO 10.00

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 17

View Details











PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 REF. DOCTOR: SELF

ACCESSION NO: 0251WJ001889
PATIENT ID: AURAM211089251
CLIENT PATIENT ID: 0123102140047

ABHA NO :

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02

RECEIVED : 21/10/2023 13:10:02 REPORTED : 22/10/2023 14:56:18

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

URIC ACID, SERUM URIC ACID METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE	6.7	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	7.8	6.4 - 8.3	g/dL
ALBUMIN, SERUM ALBUMIN METHOD: BROMOCRESOL GREEN	4.8 High	3.8 - 4.4	g/dL
GLOBULIN GLOBULIN	3.0	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM SODIUM, SERUM METHOD: 10N-SELECTIVE ELECTRODE POTASSIUM, SERUM METHOD: 10N-SELECTIVE ELECTRODE CHLORIDE, SERUM	141.1 3.95 98.2	137 - 145 3.6 - 5.0 98 - 107	mmol/L mmol/L

Interpretation(s)

METHOD: ION-SELECTIVE ELECTRODE

Sodium	Potassium	Chinalda
36618IW	Pocassium	Chloride

Dr. Akansha Jain Consultant Pathologist



Page 9 Of 17

View Details









AGE/SEX



Male

PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889
PATIENTID : AURAM211089251

CLIENT PATIENT ID: 0123102140047 ABHA NO : DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

: 34 Years

Test Report Status Final Results Biological Reference Interval Units

Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH, Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti-depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, MSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glacose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy [Normal serum chloride)

DIRECT LDL CHOLESTEROL, SERUM

LDL OHOLESTEROL, DIRECT 166 High < 100 Optimal mg/dL

100 - 129 Near or above

optimal

130 - 159 Borderline High

160 - 189 High >/= 190 Very High

METHOD: DIRECT CLEARANCE METHOD

DIRECT LDL/HDL RATIO 5.5 High 0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

METHOD: CALCULATED PARAMETER

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in

Dr. Akansha Jain Consultant Pathologist



Page 10 Of 17

View Details

View Benort









PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID: : AURAM211089251 CLIENT PATIENT ID: 0123102140047

AGE/SEX : 34 Years Male DRAWN ;21/10/2023 12:59:00 RECEIVED: 21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

the urine.

 Decreased in : Pancreatic islet cell disease with increased insulin insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia). Drugsinsulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycouria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASHA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

 bilirubin excretion (eg., obstruction and hepetitis), and abnormal bilirubin metabolism (eg., hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis. Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased uncorgugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

db>AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, climbosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

<br

 disease.Lower-then-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease,

BLOOD URSA NITROGEN (BUN), SERUM-

-(b) Causes of Increased (b) levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

-(b) Causes of decreased (b) level include Liver disease, SIADH.

CREATININE, SERUM-
b>Higher than normal level may be due to:

CREATININE, SERUM-

- Blockage in the urinary tract. Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

- stb-Lower than normal level may be due to: </br/>
- Wasthenia Gravis, Muscucphy

URIC ACID, SERUM-

- Se

<br/

Blevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the dirician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Dr. Akansha Jain Consultant Pathologist



Page 11 Of 17







PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI **NEW DELHI 110030** 8800465156

ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251 CLIENT PATIENT ID: 0123102140047

ABHA NO

AGE/SEX : 34 Years Male DRAWN ;21/10/2023 12:59:00 RECEIVED: 21/10/2023 13:10:02

REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

APPEARANCE CLEAR.

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

7.5 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE 1.010 1.003 - 1.035 SPECIFIC GRAVITY

METHOD: JONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NEGATIVE

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NEGATIVE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

NOT DETECTED KETONES NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

BLOOD NOT DETECTED NEGATIVE METHOD: PEROCIDASE ANTI PEROXIDASE

BILIRUBIN NOT DETECTED NOT DETECTED

METHOD : DIPSTICK UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

/HPF NOT DETECTED NOT DETECTED RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-5/HPE 1-2

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain **Consultant Pathologist**

Jaipur, 302015 Rajasthan, India





Page 12 Of 17







PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889
PATIENT ID: AURAM211089251
CLIENT PATIENT ID: 0123102140047

ABHA NO :

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

		i		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		
EPITHELIAL CELLS METHOD: MICROSCOPIC EXAMINATION	1-2	0-5	/HPF	
CASTS	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION CRYSTALS	NOT DETECTED			
METHOD: MICROSCOPIC EXAMINATION BACTERIA	NOT DETECTED	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED		

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain Consultant Pathologist Page 13 Of 17





View Details

View Report









PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889

PATIENTID : AURAM211089251

CLIENT PATIENTID: 0123102140047

RAM211089251 DRAWN :21/10 0123102140047 RECEIVED :21/10

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02 REPORTED :22/10/2023 14:56:18

Test Report Status	Final	Results	Biological Reference Interval	Units
---------------------------	-------	---------	-------------------------------	-------

ABHA NO

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 17

View Details

View Report









PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889

PATIENT ID : AURAM211089251 GLIENT PATIENT ID: 0123102140047

ABHA NO :

AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00

RECEIVED : 21/10/2023 13:10:02 REPORTED : 22/10/2023 14:56:18

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD: GROSS EXAMINATION

Dr. Abhishek Sharma Consultant Microbiologist

Page 15 Of 17





View Details

View Report









PATIENT NAME: GAURAV KATHURIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047 ABHA NO: AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02

REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

T3 121.61 60.0 - 181.0 ng/dL

METHOD: CHEMILUMINESCENCE

T4 12.00 High 4.5 - 10.9 μg/dL

METHOD: CHEMILUMINESCENCE TSH (ULTRASENSITIVE) METHOD: CHEMILUMINESCENCE

3.077 0.550 - 4.780

μIU/mL

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hypothyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	

Dr. Akansha Jain Consultant Pathologist



Page 16 Of 17

View Details

View Report









PATIENT NAME: GAURAV KATHURIA

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH

WEST DELHI NEW DELHI 110030 8800465156 ACCESSION NO: 0251WJ001889 PATIENT ID : AURAM211089251

CLIENT PATIENT ID: 0123102140047 ABHA NO: AGE/SEX : 34 Years Male DRAWN :21/10/2023 12:59:00 RECEIVED :21/10/2023 13:10:02

REPORTED :22/10/2023 14:56:18

Test Report Status Final Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- Test results cannot be used for Medico legal purposes.
- In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist Page 17 Of 17





View Details

View Benort







Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



Name : Mr. GAURAV KATHURIA

Age/Gender: 34 Y/Male Patient ID : 012310210047

BarcodeNo :10102901

Referred By : Self

Registration No: 68644

Registered

: 21/Oct/2023 12:59PM

Analysed

: 22/Oct/2023 01:59PM

Reported

: 22/Oct/2023 01:59PM

Panel

: ACROFEMI HEALTHCARE LTD (

MEDIWHEEL)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

wellness

*** End Of Report ***


Page 1 of 1



Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14851

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the film neters mis period







Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	-	GAURAV KATHURIA			AGE	34	The same of the sa	SEX	MALE	
REF BY	INIED	WHEEL			DATE 22/10/2			REG NO		
			A CONTRACTOR OF THE PARTY OF TH	CARDIO	GRAM F	EPOR	T			
STORY SHARE SHOW	N- POC	R/ADEQU	JATE/GO	DDVALVE						
MITRAL			NORMAL	MAL		TRICUSPID		NORM	NORMAL	
AORTIC			NORMAL		PUL	MONAR	Y:	NORMA	4L	
2D/M-N	A STATE OF THE PARTY OF T									
IVSD mn	1	10.8		IVSS mm	13	.5	AOR	TA mm	22.7	
LVID mn		38.9		LVIS mm	26	.0	LA n	im	27.4	
LVPWD	nm	10.1		LVPWS mr	n 13	.5	EF%		60%	
CHAMBE	R5				=0=					
LA			NO	NORMAL		RA		NORMAL		
LV	SERVICE STATE		NO	NORMAL		RV		NORMAL		
PERICAR	MUID		NO	NORMAL					010000	
DOPPLE	STUD	Y MITRAL	L							
PEAK VE	LOCITY	m/s E/A	0.65	/0.56	PE	AK GRAI	DIANT Mmi	-ig		
MEAN V	LOCIT	Y m/s				EAN GRA	ADIANT Mr	Hg		
MVA cm	2 (PLAN	NITMETER	(Y)		MVA cm2 (PHT)		(PHT)			
MR							5			
AORTIC										
PEAK VE	OCITY	m/s	1.05		PE	AK GRAI	DIANT Mml	ig.		
MEAN VELOCITY m/s					MEAN GRADIANT MmHg		Hg			
AR										
TRICUSP	D									
PEAK VELOCITY m/s		0.48	1 A	I PE	AK GRAE	DIANT Mm	tg.			
MEAN VELOCITY m/s			MEAN GRADIANT MmHg							
TR .			SP mmH							
PULMON	ARY			A.I. I						

PEAK GRADIANT MmHg

MEAN GRADIANT MMHg

RVEDP mmHg

IMPRESSION

PR

PEAK VELOCITY m/s

MEAN VELOCITY m/s

NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION

0.93

- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

PATIENT NAME: MR GAURAV KATHURIA	AGE & SEX: 34Y/M			
REF. by: MEDI WHEEL	DATE: 22/10/2023 ··			

USG: WHOLE ABDOMEN (Male)

LIVER : Is enlarged in size in bright echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen.

Portal vein diameter and common bile duct appear normal.

GALL : Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.

SPLEEN: Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Right Kidney:-Size: 98 x 45 mm, Left Kidney:-Size: 102 x 44 mm.

Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture,

measures: 28 x 26 x 25 mm, wt; 10 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum.

: Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION:- Hepatomegaly with fatty changes.

DR NEERA MEHTA MBBS, DMRD RMCNO.005807/14853